HOME >> MEDICINE >> NEWS
Investigational drug brings new hope to kidney cancer patients

Preliminary results from a phase II trial of an investigational drug known as BAY 43-9006 demonstrate a significant short-term benefit for patients with advanced renal cell cancer, researchers from the University of Chicago and four other centers reported at the American Association of Cancer Research meeting in Boston, November 20.

Only 10 to 15 percent of patients with metastatic kidney cancer respond to standard immunotherapy, and there are no standard effective therapies for patients who fail or can't tolerate standard immunotherapy. In this study, however, 42 percent (21 of 50) of patients had their tumors shrink at least 25 percent within the first 12 weeks. Six of those patients had a reduction of 50 percent or more.

Another 26 percent (13 patients) had their tumors stabilize within 25 percent of pre-treatment size. The remaining 32 percent left the study because of progressive disease or adverse effects, such as a painful rash or diarrhea.

"This is the most exciting thing in oncology since Gleevec," said the study's lead investigator, Mark Ratain, M.D., professor of medicine and chief of clinical pharmacology at the University of Chicago. "All but one of the kidney cancer patients in this study had advanced disease that did not respond to at least one previous systemic treatment, yet almost half of them had a rapid and very encouraging response to this drug."

The study also served to validate a new approach to phase II trial design. Most phase II trials test the effects of a new drug on patients with a specific disease, such as colon cancer, and limit the goal to determining the percentage of patients who have at least a 50% reduction in tumor size. This study, a "randomized discontinuation trial," enrolled patients with many different tumor types for 12 weeks, then randomized patients with stable disease to placebo vs. continued treatment.

"This approach allows us to test a new drug for effects in many tumor
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
20-Nov-2003


Page: 1 2 3 4 5

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. Anniversary of one of the largest hepatitis A outbreaks in the US brings experts together
8. Futuristic system brings vision to blind
9. New fund brings children from Europe for lifesaving surgery
10. Childrens Cancer Fund brings world-class pediatric cancer specialist to Dallas
11. Womens and Childrens Hospital, Adelaide brings home national Diamond Serif Award

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/15/2019)... ... March 15, 2019 , ... The National Association of Chain ... controlled substance prescriptions for Schedule II through Schedule VI, which will help prevent opioid ... will become effective January 1, 2021. , NACDS recognizes the leadership of ...
(Date:3/14/2019)... LONG BEACH, Calif. (PRWEB) , ... March 14, ... ... , Where: Future site of The Spark at Midtown - 1900 Long Beach ... Long Beach Mayor Robert Garcia join LINC Housing, county and city officials, and ...
(Date:3/14/2019)... ... March 13, 2019 , ... From humble beginnings in New York City in ... has continually offered quality, foundation level and advanced yoga teacher trainings for twenty years. ... majority of the trainings today. , The move to Thailand to set up ...
(Date:3/12/2019)... Va. (PRWEB) , ... March 13, 2019 , ... ... workshop from FDAnews and Ombu Enterprises**, March 20-21, 2019 , Arlington, VA, ... one week. , Device and diagnostics makers face a jumble of QMS regulations ...
(Date:3/12/2019)... (PRWEB) , ... March 12, 2019 , ... ... announced the availability of HIPAA training for healthcare organizations and their business associates. ... with HIPAA regulations and keep patients’ personal and health information private and secure. ...
Breaking Medicine News(10 mins):
(Date:3/13/2019)... ... , ... Not all CBD oils are created the same. The tincture offered in the Stay ... advanced nano technology, the absorption rate and bioavailability far exceed those of other brands. The ... is gluten free and contains no harsh chemicals, no metals, and is tested to be ...
(Date:3/12/2019)... , ... March 13, 2019 , ... The nation's top ... $500 off its upcoming workshops. The code to use for obtaining the discount is ... 10,000 successful therapies having been performed to date. Last year, R3 began its first ...
(Date:3/12/2019)... TORONTO (PRWEB) , ... March 12, 2019 , ... ... Identity & Access Management, and nCipher (previously Thales) for Hardware Security - Niagara ... anticipated Niagara Health Navigator. The mobile application is Ontario’s first digital health ecosystem ...
Breaking Medicine Technology:
Cached News: